Vericel’s ixmyelocel-T heart drug meets primary endpoint in phase 2b clinical trial
The drug was studied in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM), a condition in which the heart becomes enlarged and cannot pump blood
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.